Diane Brockmeier, President and CEO of Mid-America Transplant, was appointed to the Baldrige Foundation Board of Directors.
Washington, D.C. -- The Foundation for the Malcolm Baldrige National Quality Award appointed Diane Brockmeier, President and CEO of Mid-America Transplant, to a two-year term on its Board of Directors.
“This is an exciting addition to our Board, and holds great promise for the continued growth and development of the entire Baldrige Enterprise,” said Foundation President and CEO Al Faber. “Diane is a proven leader and role-model. She is highly regarded throughout her industry and currently serves as President-elect of the Association of Organ Procurement Organizations. Diane has demonstrated a thorough commitment to Baldrige and the Foundation’s mission. She will be one of our most respected ambassadors.”
“Following the Baldrige Framework for Excellence has made a tremendous impact in the communities we serve. In 2017, our work accounted for 718 lifesaving organ transplants, twice as many lives saved in a single year as when we began the Baldrige journey 15 years ago,” said Ms. Brockmeier. “The criteria continue to help us make important progress toward our vision to ensure organs and tissues are always available to those in need.”
Ms. Brockmeier has been with Mid-America Transplant for over 30 years, including serving as Executive Vice President and COO when it received the Malcolm Baldrige National Quality Award in 2015.
“After experiencing firsthand the significant impact the Baldrige criteria has made on our organization, I am honored to begin contributing as a board member for the Baldrige Foundation," said Brockmeier. "I look forward to promoting the Baldrige Enterprise and helping inspire organizations across the nation to achieve excellence in all they do.”
Baldrige is a leadership and management framework with a systems level, customer driven organizational assessment and design approach that has proven to enhance the performance of organizations across every sector of the economy compared to their non-Baldrige peers. Baldrige generates an empirically-documented return on investment of $820 in cost savings and performance enhancements for each $1 spent supporting the Baldrige Enterprise. To review the relevant data, click here: https://www.nist.gov/baldrige/how-baldrige-works/about-baldrige/baldrige-impacts